After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

On Wednesday, Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) released Phase 2 study data from the regimen of bemnifosbuvir and ruzasvir for the hepatitis C virus infection that causes liver swelling and can lead to serious liver damage.

The study met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment (SVR12).

Primary endpoint results demonstrated a 98% (208/213) SVR12 rate in the per-protocol treatment adherent patient population after eight weeks of treatment with a regimen of bemnifosbuvir and ruzasvir.

Also Read: Atea Pharmaceuticals’ COVID-19 Treatment Flunks In Late-Stage Study, Blames’ Constantly Evolving’ Virus

The efficacy evaluable patient population, which ...

Full story available on Benzinga.com